kabutan

PhoenixBio Co.,Ltd.(6190) Summary

6190
TSE Growth
PhoenixBio Co.,Ltd.
428
JPY
-3
(-0.70%)
Apr 28, 3:30 pm JST
2.68
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
15.8
PBR
1.16
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
431 JPY 2.70 USD
Previous Close Apr 27
431 JPY 2.70 USD
High Apr 28, 11:10 am
435 JPY 2.72 USD
Low Apr 28, 1:43 pm
420 JPY 2.64 USD
Volume
12,100
Trading Value
5.00M JPY 0.03M USD
VWAP
424.78 JPY 2.67 USD
Minimum Trading Value
42,800 JPY 268 USD
Market Cap
1.74B JPY 0.01B USD
Number of Trades
48
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Mid
1-Year Average
305
1-Year High Oct 22, 2025
5,640
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 332,100
Apr 17, 2026 0 334,200
Apr 10, 2026 0 329,700
Apr 3, 2026 0 329,200
Mar 27, 2026 0 330,300
Company Profile
PhoenixBio Co., Ltd. is a biotech venture originating from Hiroshima University, specializing in the production of PXB mice with high human hepatocyte replacement rates and contract testing services.
Sector
Services
PhoenixBio, a biotech venture spun off from Hiroshima University, primarily focuses on providing contract testing services for drug development using PXB mice. PXB mice are chimeric mice with livers largely replaced by human hepatocytes, used for predicting human metabolism and researching hepatitis viruses. The company's main services include pharmacokinetic studies, safety tests, and efficacy evaluations for hepatitis drugs. Additionally, PhoenixBio sells fresh human hepatocytes (PXB-cells) obtained from PXB mice. These services play a crucial role in the preclinical stages of new drug development, supporting pharmaceutical companies in their drug discovery research.